Second autologous transplant with cyclosporin/interferon alpha-induced graft versus host disease for patients who have failed first-line consolidation

M Streetly, M Kazmi, D Radia, C Hoyle, S A Schey

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

The prognosis for patients with non-Hodgkin's lymphoma (NHL) and advanced Hodgkin's disease (HD) who relapse following autologous transplant is poor. We report on a pilot study designed to evaluate the feasibility of using Cyclosporin A and interferon a to induce autologous GVHD following a second autologous transplant for relapsed lymphoma. In all, 10 patients entered the study with median age 46.5 years. Diagnosis was NHL (n = 7) or Hodgkin's lymphoma (n = 3). All had relapsed from a prior autologous transplant. The second transplant was well tolerated by all patients. Histological changes consistent with cutaneous GVHD developed in 30% of patients at a median of 22.5 days from transplant and settled spontaneously in all cases. Five patients have died ( four from progressive disease) at a median 7 months from second transplant. Five patients are still alive and in complete remission at a median of 20 months from transplant. Median overall survival for the group is 13.5 months and median relapse-free survival has not been reached at 42 months. This is a well-tolerated regimen for use in this poor-risk group of patients with lymphoma. The overall survival and event-free survival are encouraging, however further studies are necessary.
Original languageEnglish
Pages (from-to)1131 - 1135
Number of pages5
JournalBone Marrow Transplantation
Volume33
Issue number11
DOIs
Publication statusPublished - 1 Jun 2004

Fingerprint

Dive into the research topics of 'Second autologous transplant with cyclosporin/interferon alpha-induced graft versus host disease for patients who have failed first-line consolidation'. Together they form a unique fingerprint.

Cite this